282 related articles for article (PubMed ID: 21663837)
1. Lipid metabolism in treated HIV Infection.
Dubé MP; Cadden JJ
Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):429-42. PubMed ID: 21663837
[TBL] [Abstract][Full Text] [Related]
2. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
[TBL] [Abstract][Full Text] [Related]
3. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.
Rimland D; Guest JL; Hernández I; Del Rio C; Le NA; Brown WV
HIV Med; 2005 Sep; 6(5):326-33. PubMed ID: 16156880
[TBL] [Abstract][Full Text] [Related]
5. Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors.
Sension M; Deckx H
AIDS Rev; 2015; 17(1):21-36. PubMed ID: 25472015
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.
Bozzette SA; Ake CF; Tam HK; Chang SW; Louis TA
N Engl J Med; 2003 Feb; 348(8):702-10. PubMed ID: 12594314
[TBL] [Abstract][Full Text] [Related]
7. Class of antiretroviral drugs and the risk of myocardial infarction.
; Friis-Møller N; Reiss P; Sabin CA; Weber R; Monforte Ad; El-Sadr W; Thiébaut R; De Wit S; Kirk O; Fontas E; Law MG; Phillips A; Lundgren JD
N Engl J Med; 2007 Apr; 356(17):1723-35. PubMed ID: 17460226
[TBL] [Abstract][Full Text] [Related]
8. Clinical management considerations for dyslipidemia in HIV-infected individuals.
Kirchner JT
Postgrad Med; 2012 Jan; 124(1):31-40. PubMed ID: 22314112
[TBL] [Abstract][Full Text] [Related]
9. A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
Bain AM; White EA; Rutherford WS; Rahman AP; Busti AJ
Pharmacotherapy; 2008 Jul; 28(7):932-8. PubMed ID: 18576908
[TBL] [Abstract][Full Text] [Related]
10. [Lipid profile of atazanavir].
Martínez Chamorro E
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():34-40. PubMed ID: 20116615
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral therapy with heart.
Randell P; Moyle G
Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610
[TBL] [Abstract][Full Text] [Related]
12. [Lipid alterations and cardiovascular risk associated with antiretroviral therapy].
Masiá-Canuto M; Bernal-Morell E; Gutiérrez-Rodero F
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):637-48. PubMed ID: 17194390
[TBL] [Abstract][Full Text] [Related]
13. Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors.
Hiransuthikul N; Hiransuthikul P; Kanasook Y
Southeast Asian J Trop Med Public Health; 2007 Jan; 38(1):69-77. PubMed ID: 17539249
[TBL] [Abstract][Full Text] [Related]
14. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.
Guo JJ; Jang R; Louder A; Cluxton RJ
Pharmacotherapy; 2005 Aug; 25(8):1044-54. PubMed ID: 16207094
[TBL] [Abstract][Full Text] [Related]
15. [Lipid disorders in patients with HIV-induced diseases].
Chanu B; Valensi P
Presse Med; 2005 Sep; 34(15):1087-94. PubMed ID: 16334888
[TBL] [Abstract][Full Text] [Related]
16. Management of dyslipidemia in patients with human immunodeficiency virus.
Shalit P
Rev Cardiovasc Med; 2014; 15 Suppl 1():S38-46. PubMed ID: 24987862
[TBL] [Abstract][Full Text] [Related]
17. Dyslipidemia related to antiretroviral therapy.
Estrada V; Portilla J
AIDS Rev; 2011; 13(1):49-56. PubMed ID: 21412389
[TBL] [Abstract][Full Text] [Related]
18. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
19. Mild-to-moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individuals.
Mannheimer SB; Wold N; Gardner EM; Telzak EE; Huppler Hullsiek K; Chesney M; Wu AW; MacArthur RD; Matts J; Friedland G;
Clin Infect Dis; 2008 Mar; 46(6):941-5. PubMed ID: 18279044
[TBL] [Abstract][Full Text] [Related]
20. Osteopenia in HIV infection.
Carr A
AIDS Clin Care; 2001 Aug; 13(8):71-3, 78. PubMed ID: 11547460
[No Abstract] [Full Text] [Related]
[Next] [New Search]
